Our DNA Could Affect the Potency of Psychedelics in the Brain
A new study has identified that variation in genes coding for key receptors in our brains may alter the potency of psychedelic drugs. The research suggests that our genetics should be a factor in future clinical trials of these drugs’ therapeutic potential.
Epigenetic Inhibitor Can Boost Cancer Immunotherapy
An epigenetic inhibitor has shown remarkable effects in activating the immune system, priming ovarian cancer patients for immunotherapy treatment.
Cell Line Successfully Transitioned to Animal-Free Media
A new paper shows how to improve the relevance and reproducibility of research by replacing media containing serum extracted from the blood of unborn calves with animal-free media.
Trial Shows Dietary Supplement Can Prevent Hereditary Cancer
A trial in people with Lynch syndrome has shown a major preventive effect from resistant starch – found in oats, breakfast cereal and slightly green bananas – showing it can reduce the risk of some cancers by more than half.
Successful Trial of Drug for Rare Genetic Liver Disease
Researchers report on the first drug to treat alpha-1 antitrypsin deficiency-associated liver disease effectively.
Genomic Signatures Could Explain Why COVID-19 Is Severe in Some People
Researchers have discovered key human genomic signatures that could help explain why COVID-19 is severe in some people and mild in others.
New Drug Class in Development for Type 2 Diabetes
Type 2 diabetes affects millions of people worldwide, and scientists have developed PATAS, a peptide that is part of a new class of antidiabetic drugs. PATAS can correct the metabolic abnormalities leading to type 2 diabetes and insulin resistance.
Drug Delivery “Bottleneck” Identified in Stem Cells
In a recent study, researchers shed some light on why the delivery of therapeutics to cells can be so difficult.
COVID-19 Vaccines Do Not Impact Placental Health
According to research, vaccination against COVID-19 had no impact on placenta health in pregnant women.
Key Gene Is Turned On in Most Cancer Types
Physician-scientists have discovered that a gene called FOXR2 that is normally turned off in most tissues in the body is activated in at least 70 percent of cancer types and eight percent of all individual tumors.